ReviewPathology2020
Virus isolation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for diagnostic and research purposes.
Review in Pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Arzanol Inhibits Human Dihydroorotate Dehydrogenase and Shows Antiviral Activity.Journal of natural products · 2025Article
- Rapid diagnosis of viral infections and application to infection control.BMC infectious diseases · 2025Article
- Outcomes of a Structured Olfactory and Gustatory Rehabilitation Program in Children with Post-COVID-19 Smell and Taste Disturbances.Journal of clinical medicine · 2025Article
- Legacy and impact of the 1925 Geneva Protocol: one hundred years of treaties and debates on chemical and biological weapons.Frontiers in microbiology · 2025Review
- Cancer Cell Culture: The Basics and Two-Dimensional Cultures.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Essential oils block cellular entry of SARS-CoV-2 delta variant.Scientific reports · 2022Article
- Semisynthetic teicoplanin derivatives with dual antimicrobial activity against SARS-CoV-2 and multiresistant bacteria.Scientific reports · 2022Article
- Lessons from SARS‑CoV‑2 and its variants (Review).Molecular medicine reports · 2022Review
- In-utero transmission of SARS CoV-2 infection during delta variant outbreak: first Australian experience.Infection · 2022Article
- Article
- SARS-CoV-2 Antigen Test Results to Infer Active or Non-Active Virus Replication Status in COVID-19 Patients.Diagnostics (Basel, Switzerland) · 2022Article
- Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic.Emerging microbes & infections · 2021Review
- Protective Role of Combined Polyphenols and Micronutrients against Influenza A Virus and SARS-CoV-2 Infection In Vitro.Biomedicines · 2021Article
- Inactivation of SARS-CoV-2 by β-propiolactone causes aggregation of viral particles and loss of antigenic potential.Virus research · 2021Article
- Can Testing Predict SARS-CoV-2 Infectivity? The Potential for Certain Methods To Be Surrogates for Replication-Competent Virus.Journal of clinical microbiology · 2021Review
- Article
- Article
- Real Time PCR and Culture-Based Virus Isolation Test in Clinically Recovered Patients: Is the Subject Still Infectious for SARS-CoV2?Journal of clinical medicine · 2021Article
- Focus on SARS-CoV-2 and COVID-19.Pathology · 2020Article
- An ultrastructural and genomic study on the SARS-CoV-2 variant B.1.210 circulating during the first wave of COVID-19 pandemic in India.Indian journal of medical microbiologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Isolation of the new pandemic virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is essential for diagnostic and research purposes including assessment of novel therapeutics. Several primary and continuous cell lines are currently used, and new organoid and engineered cell lines are being developed for improved investigation and understanding of the human immune response to this virus. Here we review the growth of SARS-CoV-2 in reference standard cell lines, engineered cell lines and new developments in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.